Picture of Pacira Biosciences logo

PCRX Pacira Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Pacira Biosciences Inc expected to post earnings of 76  cents a share - Earnings Preview

* Pacira Biosciences Inc  PCRX.OQ   PCRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 2. 
    * The Tampa Florida-based  company is expected to report  a
3.1% increase in revenue to $174.604 million from $169.41
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Pacira Biosciences
Inc is
for earnings of 76 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pacira
Biosciences Inc is $60​, above​ its last closing price
of $35.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  0.62        0.62       0.53      Missed  -14.1
 Dec. 31 2023  0.82        0.83       0.80      Missed  -3.6
 Sep. 30 2022  0.71        0.76       0.64      Missed  -16.2​
 Jun. 30 2022  0.81        0.85       0.51      Missed  -40.1
 ​​Mar.        0.80        0.83       0.64      Missed  -23.1
 31 2022                                                
 Dec. 31 2021  0.82        0.90       0.97      Beat    7.4​
 Sep. 30 2021  0.65        0.65       0.72      Beat    10.2
 Jun. 30 2021  0.79        0.74       0.77      Beat    4.6
 This summary was machine generated July 31 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Pacira Biosciences

See all news